The HHS 503A peptide policy, in its own words

10 conditions, covering the 6 peptides listed in its Appendix A. Everything in a quote below is the policy's wording, unchanged.

HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. The policy on hhs.gov and its notice in the Federal Register.

What the conditions qualify

The sentence that introduces them.

Until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list, HHS does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance that is not a component of an FDA-approved drug product, the subject of an applicable USP or NF monograph, or on the 503A bulks list codified at 21 CFR 216.23(a), when all of the following circumstances are present:

The 10 conditions

Numbered as the policy numbers them. Headings in bold are the policy's own.

  1. 503A Interim Access List. The peptide bulk drug substance appears in Appendix A to this policy.
  2. Identity of the Peptide Bulk Drug Substance. The peptide bulk drug substance has the identity and limitations in route of administration described in Appendix B. The identity includes but is not limited to amino acid sequence, chemical structure, molecular weight, and molecular formula.
  3. Characterization. The bulk drug substance is from a facility registered under section 510 (21 U.S.C. § 360) and characterized and identified in a valid certificate of analysis (COA) that includes test results consistent with existing guidance-based criteria described by FDA (see Appendix B). This helps provide assurance that what a compounder receives from a supplier is what it claims to be and has been tested for identity, purity, potency, and the absence of harmful contaminants such as endotoxins, heavy metals, microbial contamination, and impurities.
  4. The original manufacturer of the bulk drug substance (not a subsequent packer, repacker, labeler, or distributor) is registered with FDA under section 510, is in compliance with CGMP and other FD&C requirements and the physical location of the facility is listed on the COA provided to the 503A compounder. If the peptide bulk drug substance is obtained through an FDA-registered repacker, relabeler, or reseller, that entity has itself performed and documented appropriate vendor validation of the bulk drug substance manufacturer and validation of the manufacturer's COA.
  5. Report products compounded, serious adverse events, and product quality issues to FDA and to the States where the products are compounded and sent (if different). Compounders report serious adverse events associated with the use of the compounded drug product in humans (regardless of whether or not considered drug related) and product quality issues (e.g., information concerning any bacteriological contamination, or any significant chemical, physical, or other change in the distributed drug product, or any failure of a product to meet applicable specifications) to FDA's MedWatch Safety Information and Adverse Event Reporting Program. This provides an opportunity for FDA and States to act on emerging risks. In addition, the procedure for reporting adverse events and issues with the identity, strength, purity, and/or quality of the product should be detailed on the product labeling provided to the patient. Product reporting for the compounder includes the following
    • a. Active ingredient and strength of active ingredient per unit;
    • b. Original manufacturer of the active ingredient, including unique facility identifier for the manufacturing facility; and
    • c. Dosage form and route of administration.
  6. Product labeling. Product labeling that includes the following statement: "This is a compounded drug product. Not for resale."
  7. The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A. It will be easier to attribute adverse events or clinical outcomes to a specific substance, which is essential for meaningful safety surveillance and signal detection, if compounded peptide products include a single API.
  8. Route of administration. Achieving adequate oral bioavailability of peptides is inherently difficult and complex. Therefore, if a peptide is compounded in an oral dosage form, the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans.
  9. Drug delivery device. The only drug delivery device co-packaged or containing the compounded drug is an FDA 510(k)-cleared syringe. More complex drug delivery devices introduce additional patient risk.
  10. The drug product is compounded in compliance with all other applicable requirements of the FD&C Act including that the drug product not be compounded under insanitary conditions (21 U.S.C. § 351(a)(2)(A)) and section 503A's (21 U.S.C. 353a) patient specific prescription requirement.

The 6 peptides in Appendix A

Condition 1 limits the policy to these. Each link opens what all fifty states published about that peptide.

A peptide not in this list is not named by the policy. That says nothing either way about other rules on it.

Routes of administration in Appendix B

Condition 2 points to Appendix B. Its entries for these two state their dosage forms in one sentence; the other four entries describe identity without such a sentence, so none is shown for them.

BPC-157

Based on the identified updated information, enforcement discretion for BPC-157 acetate is appropriate for subcutaneous, intramuscular, oral, and topical dosage forms that are compounded from API accompanied by a certificate of analysis (CoA) meeting the conditions of this policy.

TB-500

Based on the identified updated information, enforcement discretion for TB-500 acetate appropriate for subcutaneous or intramuscular injectable dosage forms that are compounded from API accompanied by a CoA meeting the conditions of this policy.

The copy we read

hhs.gov refuses our automated requests, so this text comes from a copy of the PDF downloaded by hand on 2026-11-05 and transcribed with only the spacing that PDF extraction adds inside words closed up. Its SHA-256 fingerprint is 65853534ddfa6c4aabe7116514b239054a3d936fbd6bd4b6901cdef086480321, so anybody holding the same file can check it is the one we quote. If HHS publishes a new version, this page still shows the copy above until we read the new one.

We report what each source says, in its own words. We do not give legal advice. Nothing on record is not permission.

Every rule we read, and the order checks, are on the free map.